Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases

NCT03314974 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.

NCT NCT03314974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03314974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases
Lead sponsor
Masonic Cancer Center, University of Minnesota
Phase
Phase 2
Overall status
Recruiting
Start date
March 30, 2018
Completion date
June 10, 2028
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acquired bone marrow failure syndromes, acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, biphenotypic/undifferentiated/prolymphocytic leukemias, burkitt lymphoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, diffuse large cell non hodgkins lymphoma, follicular lymphoma, high grade non-hodgkin's lymphoma, adult, high risk anemia, juvenile myelomonocytic leukemia, lymphoblastic lymphoma, lymphoma, lymphoplasmacytic lymphoma, mantle-cell lymphoma, marginal zone b-cell lymphoma, mrd positive leukemia, multiple myeloma, myelodysplasia, myelofibrosis, myeloproliferative neoplasms, natural killer cell malignancies, plasma cell leukemia, prolymphocytic leukemia, refractory anemia, small lymphocytic lymphoma